G1 Therapeutics sell quelbe60
Start price
24.06.24
/
50%
€2.25
Target price
24.06.25
-
Performance (%)
-0.62%
End price
06.07.24
€2.24
Summary
This prediction ended on 06.07.24 with a price of €2.24. The SELL prediction by quelbe60 for G1 Therapeutics closed nearly unchanged from the start price. quelbe60 has 50% into this predictionG1 Therapeutics is a biopharmaceutical company that focuses on the discovery, development, and commercialization of small molecule therapeutics for the treatment of cancer. Their lead product candidate, Trilaciclib, is designed to improve the outcomes of chemotherapy by preserving hematopoietic stem cells and immune system function. G1 Therapeutics is also developing therapeutics for lung cancer, glioblastoma multiforme, and other solid tumors. The company went public in May 2017 and is listed on the NASDAQ exchange under the symbol GTHX.
Performance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| G1 Therapeutics | - | - | - |
| iShares Core DAX® | 0.734% | -0.964% | 17.910% |
| iShares Nasdaq 100 | -2.686% | -2.409% | 4.267% |
| iShares Nikkei 225® | -2.261% | -4.038% | 10.420% |
| iShares S&P 500 | -1.346% | -1.510% | 1.615% |
According to quelbe60 what are the pros and cons of G1 Therapeutics for the foreseeable future?
Pros
Cons
Probably not worthwhile Investment
Comments by quelbe60 for this prediction
In the thread G1 Therapeutics diskutieren
Sell G1 Therapeutics
In the thread Trading G1 Therapeutics
Stopped prediction by quelbe60 for G1 Therapeutics
G1 Therapeutics
Start price
Target price
Perf. (%)
€3.15
28.05.24
28.05.24
-
28.05.25
28.05.25
-28.57%
23.06.24
23.06.24
Probably not worthwhile Investment
